ClinicalTrials.gg
RecruitingNCT06914427Updated Nov 10, 2026

PET/CT Imaging Study With Simultaneous Dual-nuclide Imaging Technique

An interventional study of PET/CT in Prostatic Neoplasms, Glioma and Lung Cancer, sponsored by Xijing Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Xijing Hospital · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.
Updated Nov 10, 2026Now RecruitingSite recruiting status changed+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
35
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Prostatic Neoplasms by Xijing Hospital — 10 open to participants now, 10 under way, none of them phase 3. Prostatic Neoplasms · Xijing Hospital.

Started
2025
with 1 other
No phase
3 of 10
3 open now
Registered
5th of 10
by date

Among the 10 studies in Prostatic Neoplasms by Xijing Hospital, this one is one of 2 that started in 2025, is one of 3 with no phase, and was the 5th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

10 of the 10 studies in Prostatic Neoplasms by Xijing Hospital are open now, in 2 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Prostatic Neoplasms by Xijing Hospital, or all of them as a file.
02

Study summary

This is a study using a self-control approach and is expected to recruit 35 volunteers, including prostate cancer patients, neuroendocrine tumour patients, glioma patients, lung cancer patients, and normal volunteers, to undergo dual-tracer PET/CT imaging and to validate the separation performance and quantitative accuracy of simultaneous dual-tracer imaging in humans.

03

Conditions studied

  • Prostatic Neoplasms
  • Glioma
  • Lung Cancer
  • Neuroendocrine Tumors
04

Who can participate

The criteria were revised on the registry on Nov 10, 2026. See what changed

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age: 18 \~75 years old (including boundary values);
  • Gender: male or female;
  • Normal volunteers: males weighing ≥50kg, females weighing ≥45kg, and [BMI = weight (kg)/height 2 (m2)] within the range of 19.0 \~ 26.0kg/m2 (including borderline values);
  • patients with prostate cancer: patients with -confirmed biochemical or primary diagnosed prostate cancer with highly suspected systemic on conventional imaging or PSA levels;
  • patients with neuroendocrine tumour patients: patients with NET (G2-G3) or NEC confirmed by pathology and highly suspected of having more than 3 metastases by conventional imaging;
  • patients with glioma:patients with glioma confirmed by pathology or highly suspected by enhanced MRI and proposed to undergo surgical resection; patients with Lung cancer: patients with lung cancer or suspected recurrent lung cancer.
  • Subjects can fully understand and voluntarily participate in this experiment and sign an form.

Exclusion criteria

Exclusion Criteria:

  • Those who cannot tolerate intravenous drug delivery methods (e.g., history of needle and blood sickness);
  • those with alcohol allergy;
  • and those who, in the opinion of the investigator, are unsuitable to undergo or are unable to complete imaging studies such as PET for specific reasons;
  • Under 18 years of age or score > 2;
  • Less than 1 month after completion of radiotherapy and less than 2 months after completion of octreotide treatment in patients with neuroendocrine tumours;
  • Women during pregnancy and breastfeeding;
  • Practitioners requiring prolonged exposure to radioactive conditions;
  • Serious diseases of heart, kidney, lung, vascular, nervous and mental systems, immunodeficiency diseases and hepatitis/cirrhosis;
  • Participation in other interventional clinical trials within 1 month prior to screening;
  • Presence of other conditions that, in the opinion of the investigator, make participation in this study unsuitable.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
35 participants (estimated)

Study arms

  • Experimental
    before-after study in the same patient

    Approximately 35 volunteers are planned to be included in this study. The screened subjects will be scanned with a mononuclide 68Ga/124I labeled tracer on the first day, a mononuclide 18F labeled tracer on another day, and a dual-nuclide 68Ga/124I +18F tracers on another day, to validate the separation performance and quantitative accuracy of simultaneous dual-tracer imaging method in humans.

    Diagnostic Test: PET/CT

Interventions

  • Diagnostic testPET/CT

    Scanning time: acquisition starts 60±10 minutes after 68Ga/18F labeled tracer injection; 124I labeled tracer around 24h after injection; Scanning parameters: whole-body imaging (cranial vault to mid-thigh), routine single-nuclide 3 min/bed; dual-nuclide 5-15min/bed.

06

What researchers measure

Primary outcomes

  1. Signal retention

    using the 68Ga, 124I, 18F individual imaging images as the gold standard and calculating the retention of the letter lesion area number on the 68Ga/18F and 124I/18F separate images

    Time frame: 1 day from injection of the tracer

  2. Clearance

    calculated by using the 68Ga, 124I and 18F individual imaging images as the gold standard, and calculating the signal clearance of the lesion area on the 18F/68Ga and 18F/124I separate images

    Time frame: 1 day from injection of the tracer

  3. SUVmax difference values

    paired t-test comparing the difference in SUVmax values of lesions on gold standard versus 68Ga/18F and 124I/18F separation images

    Time frame: 1 day from injection of the tracer

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Mar 2027, 23 months after the start.

Of 1,104 non-industry interventional studies with no phase under Prostatic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 87. This study's planned 23 months is below that.

Counting every sponsor, half of 1,162 studies reached it within 43 months; a quarter within 22 and three quarters within 86.

Start moved once since we started tracking on Sep 25, 2026: Mar 2025 → Apr 2025, on Nov 10, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 30, 2025
First posted
Apr 6, 2025
StartActual
Apr 1, 2025was Mar 2025
Primary completionEst.
Mar 1, 2027
CompletionEst.
Mar 1, 2027
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 10, 2026
Sites
Department of Nuclear Medicine,Xijing Hospital, Fourth Military Medical University is now Recruiting
Nov 10, 2026
Start date
Mar 28, 2025→Apr 1, 2025 (actual)
Nov 10, 2026
Eligibility
6 inclusion criteria added, 1 removed; 10 exclusion criteria added, 1 removed
What changed in the criteria
Inclusion criteria
  • RemovedAge: 18 ~75 years old (including boundary values); Gender: male or female; Normal volunteers: males weighing ≥50kg, females weighing ≥45kg, and body mass index [BMI = weight (kg)/height 2 (m2)] within the range of 19.0 ~ 26.0kg/m2 (including borderline values); patients with prostate cancer: patients with pathologically-confirmed biochemical relapsed or primary diagnosed prostate cancer with highly suspected systemic metastases on conventional imaging or PSA levels; patients with neuroendocrine tumour patients: patients with NET (G2-G3) or NEC confirmed by pathology and highly suspected of having more than 3 metastases by conventional imaging; patients with glioma: patients with glioma confirmed by pathology or highly suspected by enhanced MRI and proposed to undergo surgical resection; patients with Parkinson's syndrome: patients with high clinical suspicion of Parkinson's syndrome.
  • AddedAge: 18 ~75 years old (including boundary values);
  • AddedGender: male or female;
  • AddedNormal volunteers: males weighing ≥50kg, females weighing ≥45kg, and body mass index [BMI = weight (kg)/height 2 (m2)] within the range of 19.0 ~ 26.0kg/m2 (including borderline values);
  • Addedpatients with prostate cancer: patients with pathologically-confirmed biochemical relapsed or primary diagnosed prostate cancer with highly suspected systemic metastases on conventional imaging or PSA levels;
  • Addedpatients with neuroendocrine tumour patients: patients with NET (G2-G3) or NEC confirmed by pathology and highly suspected of having more than 3 metastases by conventional imaging;
  • Addedpatients with glioma:patients with glioma confirmed by pathology or highly suspected by enhanced MRI and proposed to undergo surgical resection; patients with Lung cancer: patients with lung cancer or suspected recurrent lung cancer.
Exclusion criteria
  • RemovedThose who cannot tolerate intravenous drug delivery methods (e.g., history of needle and blood sickness); those with alcohol allergy; and those who, in the opinion of the investigator, are unsuitable to undergo or are unable to complete imaging studies such as PET for specific reasons; Under 18 years of age or ECOG score > 2; Less than 1 month after completion of radiotherapy and less than 2 months after completion of octreotide treatment in patients with neuroendocrine tumours; Women during pregnancy and breastfeeding; Practitioners requiring prolonged exposure to radioactive conditions; Serious diseases of heart, kidney, lung, vascular, nervous and mental systems, immunodeficiency diseases and hepatitis/cirrhosis; Participation in other interventional clinical trials within 1 month prior to screening; Presence of other conditions that, in the opinion of the investigator, make participation in this study unsuitable.
  • AddedThose who cannot tolerate intravenous drug delivery methods (e.g., history of needle and blood sickness);
  • Addedthose with alcohol allergy;
  • Addedand those who, in the opinion of the investigator, are unsuitable to undergo or are unable to complete imaging studies such as PET for specific reasons;
  • AddedUnder 18 years of age or ECOG score > 2;
  • AddedLess than 1 month after completion of radiotherapy and less than 2 months after completion of octreotide treatment in patients with neuroendocrine tumours;
  • AddedWomen during pregnancy and breastfeeding;
  • AddedPractitioners requiring prolonged exposure to radioactive conditions;
  • AddedSerious diseases of heart, kidney, lung, vascular, nervous and mental systems, immunodeficiency diseases and hepatitis/cirrhosis;
  • AddedParticipation in other interventional clinical trials within 1 month prior to screening;
  • AddedPresence of other conditions that, in the opinion of the investigator, make participation in this study unsuitable.
Nov 10, 2026
Primary outcomes
3 description edited
What changed in the outcomes
  • DescriptionClearance: how it is measured was reworded
  • DescriptionSUVmax difference values: how it is measured was reworded
  • DescriptionSignal retention: how it is measured was reworded
Nov 10, 2026
Contact
Study contact changed: g•••@163.com · •••9177→y•••@163.com · •••1101. See the current contact
Nov 10, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Department of Nuclear Medicine,Xijing Hospital, Fourth Military Medical University · Xi'an, ChinaContact g•••@163.com · •••9177→y•••@163.com · •••1101
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Not yet recruiting→Recruiting
    Department of Nuclear Medicine,Xijing Hospital, Fourth Military Medical University is now Recruiting
    Start date Mar 28, 2025→Apr 1, 2025 (now actual)
    Eligibility 6 inclusion criteria added, 1 removed; 10 exclusion criteria added, 1 removed
    What changed in the criteria
    Inclusion criteria
    • RemovedAge: 18 ~75 years old (including boundary values); Gender: male or female; Normal volunteers: males weighing ≥50kg, females weighing ≥45kg, and body mass index [BMI = weight (kg)/height 2 (m2)] within the range of 19.0 ~ 26.0kg/m2 (including borderline values); patients with prostate cancer: patients with pathologically-confirmed biochemical relapsed or primary diagnosed prostate cancer with highly suspected systemic metastases on conventional imaging or PSA levels; patients with neuroendocrine tumour patients: patients with NET (G2-G3) or NEC confirmed by pathology and highly suspected of having more than 3 metastases by conventional imaging; patients with glioma: patients with glioma confirmed by pathology or highly suspected by enhanced MRI and proposed to undergo surgical resection; patients with Parkinson's syndrome: patients with high clinical suspicion of Parkinson's syndrome.
    • AddedAge: 18 ~75 years old (including boundary values);
    • AddedGender: male or female;
    • AddedNormal volunteers: males weighing ≥50kg, females weighing ≥45kg, and body mass index [BMI = weight (kg)/height 2 (m2)] within the range of 19.0 ~ 26.0kg/m2 (including borderline values);
    • Addedpatients with prostate cancer: patients with pathologically-confirmed biochemical relapsed or primary diagnosed prostate cancer with highly suspected systemic metastases on conventional imaging or PSA levels;
    • Addedpatients with neuroendocrine tumour patients: patients with NET (G2-G3) or NEC confirmed by pathology and highly suspected of having more than 3 metastases by conventional imaging;
    • Addedpatients with glioma:patients with glioma confirmed by pathology or highly suspected by enhanced MRI and proposed to undergo surgical resection; patients with Lung cancer: patients with lung cancer or suspected recurrent lung cancer.
    Exclusion criteria
    • RemovedThose who cannot tolerate intravenous drug delivery methods (e.g., history of needle and blood sickness); those with alcohol allergy; and those who, in the opinion of the investigator, are unsuitable to undergo or are unable to complete imaging studies such as PET for specific reasons; Under 18 years of age or ECOG score > 2; Less than 1 month after completion of radiotherapy and less than 2 months after completion of octreotide treatment in patients with neuroendocrine tumours; Women during pregnancy and breastfeeding; Practitioners requiring prolonged exposure to radioactive conditions; Serious diseases of heart, kidney, lung, vascular, nervous and mental systems, immunodeficiency diseases and hepatitis/cirrhosis; Participation in other interventional clinical trials within 1 month prior to screening; Presence of other conditions that, in the opinion of the investigator, make participation in this study unsuitable.
    • AddedThose who cannot tolerate intravenous drug delivery methods (e.g., history of needle and blood sickness);
    • Addedthose with alcohol allergy;
    • Addedand those who, in the opinion of the investigator, are unsuitable to undergo or are unable to complete imaging studies such as PET for specific reasons;
    • AddedUnder 18 years of age or ECOG score > 2;
    • AddedLess than 1 month after completion of radiotherapy and less than 2 months after completion of octreotide treatment in patients with neuroendocrine tumours;
    • AddedWomen during pregnancy and breastfeeding;
    • AddedPractitioners requiring prolonged exposure to radioactive conditions;
    • AddedSerious diseases of heart, kidney, lung, vascular, nervous and mental systems, immunodeficiency diseases and hepatitis/cirrhosis;
    • AddedParticipation in other interventional clinical trials within 1 month prior to screening;
    • AddedPresence of other conditions that, in the opinion of the investigator, make participation in this study unsuitable.
    Primary outcomes 3 description edited
    What changed in the outcomes
    • DescriptionClearance: how it is measured was reworded
    • DescriptionSUVmax difference values: how it is measured was reworded
    • DescriptionSignal retention: how it is measured was reworded
    Contact Study contact changed: g•••@163.com · •••9177→y•••@163.com · •••1101. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Department of Nuclear Medicine,Xijing Hospital, Fourth Military Medical University · Xi'an, ChinaContact g•••@163.com · •••9177→y•••@163.com · •••1101
    + 8 other changes: index terms, identifiers, verification date, oversight details, description, conditions, design details and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06914427
Lead sponsor
Xijing Hospital
Responsible party
Sponsor
First posted
Apr 6, 2025
Start date
Apr 1, 2025
Primary completion
Mar 1, 2027 (estimated)
Completion
Mar 1, 2027 (estimated)
Last update
Nov 10, 2026

Study contacts

Qiqi Yang Qiqi Yang
Contact
yangqiqi_1101@163.com
0086+18992601101

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion